Gene · 8607
Papers1,564
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,564
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive bioinformatics analysis of EXOSC family genes in head and neck squamous cell carcinoma. | Sci Rep | 2025 | 40830179 | PubTator, text mining | PubMed |
| Regulation of DNA repair gene expression by PRMT5. | MicroPubl Biol | 2025 | 40735501 | PubTator, text mining | PubMed |
| Aedes aegypti encodes an ATPase-active RUVBL1/2 complex. | Int J Biol Macromol | 2025 | 40505928 | PubTator, text mining | PubMed |
| Detection of Anti-RuvBL1/2 Autoantibodies by Targeted Liquid Chromatography-Tandem Mass Spectrometry. | J Appl Lab Med | 2025 | 40498123 | PubTator, text mining | PubMed |
| Establishment of interpretable cytotoxicity prediction models using machine learning analysis of transcriptome features. | Acta Pharm Sin B | 2025 | 40370539 | PubTator, text mining | PubMed |
| Mechanistic insights into CLNS1A-mediated chemoresistance and tumor progression in non-small cell lung cancer. | Cancer Lett | 2025 | 40345428 | PubTator, text mining | PubMed |
| Comprehensive Analysis of the Multi-Target Binding Mechanism of Doxorubicin: Integrating Protein Microarray Screening, Molecular Docking, and Molecular Dynamics Simulation. | Arch Pharm (Weinheim) | 2025 | 40345153 | PubTator, text mining | PubMed |
| Genome-wide CRISPR activation screen identifies ARL11 as a sensitivity determinant of PARP inhibitor therapy. | Cancer Gene Ther | 2025 | 40123001 | PubTator, text mining | PubMed |
| A large-scale benchmark for network inference from single-cell perturbation data. | Commun Biol | 2025 | 40069299 | PubTator, text mining | PubMed |
| In silico protein structural analysis of PRMT5 and RUVBL1 mutations arising in human cancers. | Cancer Genet | 2025 | 39874873 | PubTator, text mining | PubMed |
| PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells. | Oncogene | 2025 | 39695328 | PubTator, text mining | PubMed |
| Regulation of the β‑catenin/LEF‑1 pathway by the siRNA knockdown of RUVBL1 expression inhibits breast cancer cell proliferation, migration and invasion. | Oncol Rep | 2025 | 39670302 | PubTator, text mining | PubMed |
| The Lyn/RUVBL1 Complex Promotes Colorectal Cancer Liver Metastasis by Regulating Arachidonic Acid Metabolism Through Chromatin Remodeling. | Adv Sci (Weinh) | 2025 | 39665272 | PubTator, text mining | PubMed |
| RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD. | Life Sci Alliance | 2025 | 39638345 | PubTator, text mining | PubMed |
| Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. | Signal Transduct Target Ther | 2024 | 39627201 | PubTator, text mining | PubMed |
| Cotranslational molecular condensation of cochaperones and assembly factors facilitates axonemal dynein biogenesis. | Proc Natl Acad Sci U S A | 2024 | 39541357 | PubTator, text mining | PubMed |
| The HSP90/R2TP Quaternary Chaperone Scaffolds Assembly of the TSC Complex. | J Mol Biol | 2024 | 39490680 | PubTator, text mining | PubMed |
| Transcriptional control of interferon-stimulated genes. | J Biol Chem | 2024 | 39276937 | PubTator, text mining | PubMed |
| A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer. | Cell Death Dis | 2024 | 39217152 | PubTator, text mining | PubMed |
| Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma. | Int J Mol Sci | 2024 | 39201707 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8607/papers?page=3